Abstract Number: 0925 • ACR Convergence 2021
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…Abstract Number: 1451 • ACR Convergence 2021
Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions
Background/Purpose: According to the 2020 American Health Ranking System, 26% of adults are physically inactive with a higher prevalence found in adults ages ≥65 years.…Abstract Number: PP13 • ACR Convergence 2021
CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…Abstract Number: 0955 • ACR Convergence 2021
The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was evaluated in ANCA-associated vasculitis (AAV). Efficacy and safety results were reported previously. Health-related quality of life (HRQoL)…Abstract Number: 1591 • ACR Convergence 2021
Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)
Background/Purpose: The COVID-19 pandemic has impacted wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs). The aim is to assess wellbeing its associated factors in…Abstract Number: 0326 • ACR Convergence 2020
Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
Background/Purpose: Flares in PsA, presenting as periods of acute disease activity, are thought to negatively impact patients’ lives. This has not been extensively studied in…Abstract Number: 1081 • ACR Convergence 2020
Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies
Background/Purpose: Patient-reported outcomes (PROs) are increasingly used in rheumatology. Such outcomes are under-reported in autoimmune inflammatory myopathies (AIM) especially in incident cohorts. The objective of…Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…Abstract Number: 1102 • ACR Convergence 2020
Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment
Background/Purpose: To investigate whether neuropathic pain is present in patients with inflammatory hand OA, to investigate characteristics of those patients and the impact of neuropathic…Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…Abstract Number: 0353 • ACR Convergence 2020
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Background/Purpose: A treat-to-target approach in psoriatic arthritis (PsA) was recommended by EULAR and GRAPPA to achieve remission (REM) or low disease activity (LDA), by regular…Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 30
- Next Page »